• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

    11/6/24 7:14:00 PM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance
    Get the next $CYTH alert in real time by email

    NEWARK, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), today reported its financial results for the fourth quarter and the full fiscal year ended July 31, 2024.

    "During fiscal 2024, we made significant progress on our strategy to advance our existing portfolio and to invest in, develop and commercialize clinical stage assets in areas of high unmet medical need. Specifically, we are extremely pleased to have entered into a merger agreement with Cyclo Therapeutics (NASDAQ:CYTH)," said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are encouraged that Cyclo Therapeutics has fully enrolled its pivotal Phase 3 study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, and results from the 48-week interim analysis are expected in the middle of 2025. Despite recent FDA approvals, we believe that Trappsol® Cyclo™ has the potential to be a market leader. We anticipate a shareholder vote and closing the merger with Cyclo Therapeutics in the coming months."

    Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2024 Financial Results

    As of July 31, 2024, we had cash, cash equivalents and marketable securities of $65.9 million.

    For the three months ended July 31, 2024, we recorded a net loss from continuing operations attributable to Rafael Holdings of $4.5 million, or $0.19 per diluted share, versus a net gain from continuing operations of $1.3 million, or $0.06 per diluted share, in the year ago period.

    Research and development expenses were $1.5 million for the three months ended July 31, 2024, compared to $1.3 million in the year ago period. The year over year increase relates to activity at Cornerstone and Day Three Labs, which were consolidated with Rafael Holdings during fiscal 2024.

    For the three months ended July 31, 2024, general and administrative expenses were $2.3 million. For the same period in the prior year, general and administrative expenses were $1.4 million. The increase was primarily due to additional expenses from Cornerstone and Day Three Labs, which were consolidated with Rafael Holdings during fiscal 2024, as well as increased professional fees related to the Cornerstone and Day Three Labs acquisitions.

    Rafael Holdings, Inc. Full Fiscal Year 2024 Financial Results

    For the twelve months ended July 31, 2024, we recorded a net loss from continuing operations attributable to Rafael Holdings of $34.4 million, or $1.45 per diluted share, versus a net loss from continuing operations of $8.4 million, or $0.36 per diluted share, in the year ago period. The net loss recorded during fiscal year 2024 was driven by an in-process research and development expense of $89.9 million related to the Cornerstone acquisition, a loss of $1.6 million on our initial investment in Day Three Labs, offset by a recovery of receivables from Cornerstone of $31.3 million and realized and unrealized gains on our investment in Cyclo Therapeutics. During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 84% of the shares outstanding. We began reporting consolidated financial results for Day Three Labs in January 2024 and Cornerstone Pharmaceuticals in March 2024.

    Research and development expenses were $4.2 million for the fiscal year ended July 31, 2024, compared to $6.3 million in the year ago period. The year over year reduction is due to the winding down of early-stage programs, including at Barer Institute.

    For the fiscal year ended July 31, 2024, general and administrative expenses were $8.9 million versus $8.9 million in the same period in the prior year. The decrease in general and administrative expenses at Rafael Holdings was offset by additional G&A expenses from Cornerstone and Day Three Labs as well as increased professional fees related to the two acquisitions in Fiscal 2024.

    About Rafael Holdings, Inc.

    Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies including an investment in (and planned merger with) Cyclo Therapeutics Inc. (NASDAQ:CYTH), a biotechnology company dedicated to developing Trappsol® Cyclo™, which is being evaluated in clinical trials, including an ongoing Phase 3 trial for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal, and progressive genetic disorder.  Rafael also holds a majority equity interest in LipoMedix Pharmaceuticals Ltd. a clinical stage pharmaceutical company, Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and a majority interest in Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company. Rafael also holds a majority interest in Rafael Medical Devices, LLC., an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings enabling them to bring to market better, cleaner, more precise and predictable versions by utilizing Day Three's pharmaceutical-grade technology and innovation like Unlokt™. The Company's primary focus is to expand our investment portfolio through opportunistic and strategic investments including therapeutics, which address high unmet medical needs. Upon closing of the planned merger with Cyclo, the Company intends to focus its efforts on making Trappsol® Cyclo™ its lead clinical program.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Contact:

    Barbara Ryan

    [email protected]

    (203) 274-2825

     
    RAFAEL HOLDINGS, INC.
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except share and per share data)
         
         
      July 31, 2024 July 31, 2023
    ASSETS    
         
    CURRENT ASSETS    
    Cash and cash equivalents $2,675  $21,498 
    Available-for-sale securities  63,265   57,714 
    Interest receivable  515   387 
    Convertible note receivable, related party  5,191   — 
    Accounts receivable, net of allowance for doubtful accounts of $245 at July 31, 2024 and July 31, 2023  426   213 
    Prepaid expenses and other current assets  430   914 
    Convertible note receivable, related party  0   1,921 
    Investment in equity securities  —   294 
    Total current assets  72,502   82,941 
         
    Property and equipment, net  2,120   1,695 
    Investments – Cyclo  12,010   4,763 
    Investments – Hedge Funds  2,547   4,984 
    Investment – Day Three  —   2,797 
    Investments – Other Pharmaceuticals  —   65 
    Convertible note receivable  1,146   — 
    Goodwill  3,050   — 
    Intangible assets, net  1,847   — 
    In-process research and development  1,575   1,575 
    Other assets  35   9 
    TOTAL ASSETS $96,832  $98,829 
         
    LIABILITIES AND EQUITY    
    CURRENT LIABILITIES    
    Accounts payable $2,556  $333 
    Accrued expenses  1,798   763 
    Convertible notes payable  614   — 
    Other current liabilities  113   1,023 
    Due to related parties  733   26 
    Installment note payable  1,700   — 
    Total current liabilities  7,514   2,145 
         
    Accrued expenses, noncurrent  2,982   — 
    Convertible notes payable, noncurrent  73   — 
    Other liabilities  5   55 
    TOTAL LIABILITIES  10,574   2,200 
         
    COMMITMENTS AND CONTINGENCIES    
         
    EQUITY    
    Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2024 and July 31, 2023  8   8 
    Class B common stock, $0.01 par value; 200,000,000 shares authorized, 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024, and 23,635,709 shares issued and 23,490,527 shares outstanding as of July 31, 2023  238   236 
    Additional paid-in capital  280,048   264,010 
    Accumulated deficit  (201,743)  (167,333)
    Treasury stock, at cost; 101,487 and 0 Class B shares as of July 31, 2024 and July 31, 2023, respectively  (168)  — 
    Accumulated other comprehensive income (loss) related to unrealized income on available-for-sale securities  111   (353)
    Accumulated other comprehensive income related to foreign currency translation adjustment  3,691   3,725 
    Total equity attributable to Rafael Holdings, Inc.  82,185   100,293 
    Noncontrolling interests  4,073   (3,664)
    TOTAL EQUITY  86,258   96,629 
         
    TOTAL LIABILITIES AND EQUITY $96,832  $98,829 
         



     
    RAFAEL HOLDINGS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

    (in thousands, except share and per share data)

            
     Three Months Ended July 31, Year Ended July 31,
     2024 2023 2024 2023
    Revenues$165  $68  $637  $279 
            
    Cost of infusion Technology revenue 69   -   154   - 
    G&A Expenses 2,330   1,395   8,854   8,932 
    R&D Expenses 1,543   1,266   4,170   6,312 
    In-process research and development expense -   0   89,861   - 
    Depreciation and amortization 68   18   225   78 
    Operating Loss (3,845)  (2,611)  (102,627)  (15,043)
    Interest income 606   -   2,383   3,253 
    Impairment of investments - Other Pharmaceuticals -   17   -   (334)
    Loss on initial investment in Day Three upon acquisition -   -   (1,633)  - 
    Realized gain on available-for-sale securities 251   -   1,772   154 
    Realized gain (loss) on investment in equity securities -   -   (46)  309 
    Unrealized gain on investment in equity securities -   -   -   33 
    Realized gain on investment - Cyclo -   -   424   - 
    Unrealized gain on investment - Cyclo (3,162)  2,663   37   2,663 
    Unrealized gain on convertible notes receivable, due from Cyclo 1,191   -   1,191   - 
    Unrealized (loss) gain on investment - Hedge Funds 181   100   63   220 
    Recovery of receivables from Cornerstone -   -   31,305   - 
    Interest expense (163)  -   (248)  - 
    Other income -   1,294   118   - 
    Income (loss) before incomes taxes from continuing operations (4,941)  1,463   (67,261)  (8,745)
    Benefit from taxes 87   (4)  2,680   255 
    Equity in loss of Day Three -   (203)  (422)  (203)
    Consolidated net loss from continuing operations (4,854)  1,256   (65,003)  (8,693)
            
    Discontinued Operations       
    Loss from discontinued operations related to 520 Property   (65)  -   (306)
    Gain on disposal of 520 Property   0   -   6,784 
    Income from discontinued operations -   (65)  -   6,478 
            
    Consolidated net loss (4,854)  1,191   (65,003)  (2,215)
    Net loss attributable to noncontrolling interests (386)  (28)  (30,593)  (339)
    Net loss attributable to Rafael Holdings, Inc.$(4,468) $1,163  $(34,410) $(1,876)
            
            
    Continuing operations earnings (loss) per share       
    Net loss from continuing operations$(4,854) $1,256  $(65,003) $(8,693)
    Net loss attributable to noncontrolling interests (386)  -28   (30,593)  (339)
    Numerator for loss per share from continuing operations$(4,468) $1,284  $(34,410) $(8,354)
            
    Discontinued operations earnings income per share       
    Numerator for income from discontinued operations$-  $(65) $-  $6,478 
            
    Earnings (loss) per share - Basic and Diluted       
    Continuing operations$(0.19) $0.06  $(1.45) $(0.36)
    Discontinued operations -   -   -   0.28 
    Total basic earnings (loss) per common share$(0.19) $0.06  $(1.45) $(0.08)
            
    Weighted average number of shares used in calculation of earnings (loss) per share - basic and diluted 23,916,839   22,263,211   23,745,516   23,263,211 
            


    Primary Logo

    Get the next $CYTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYTH
    $RFL

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $CYTH
    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did not hold shares in street name and have not submitted their letter of transmittal to Equiniti Trust Company LLC (the Company's transfer agent), and wish to participate in the rights offering, should send their

      5/5/25 7:00:00 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

      NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol® Cyclo™ in the event of a positive interim result from the 48-week interim analysis of the TransportNPC™ Phase 3 clinical t

      4/29/25 4:30:00 PM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role with the Company. Rafael's Executive Chairman and Chairman of the Board, Howard Jonas will assume the role of CEO. During his tenure as CEO, Bill played a pivotal role in identifying investment opportu

      4/24/25 4:15:00 PM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Financials

    Live finance-specific insights

    See more
    • Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

      Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

      10/28/21 7:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $CYTH
    $RFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CYTH
    $RFL
    SEC Filings

    See more

    $CYTH
    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CYTH
    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Maxim Group reiterated coverage on Cyclo Therapeutics with a new price target

      Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously

      2/10/21 8:07:06 AM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rafael Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:49:29 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 424B3 filed by Rafael Holdings Inc.

      424B3 - Rafael Holdings, Inc. (0001713863) (Filer)

      5/6/25 4:40:50 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form 8-K/A filed by Rafael Holdings Inc.

      8-K/A - Rafael Holdings, Inc. (0001713863) (Filer)

      5/5/25 7:15:49 AM ET
      $RFL
      Real Estate
      Finance
    • Chief Executive Officer Conkling William was granted 27,454 units of Class B Common Stock, increasing direct ownership by 5% to 564,455 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/24/25 3:18:53 PM ET
      $RFL
      Real Estate
      Finance
    • New insider Sieger Markus claimed ownership of 155,182 units of Class B Common Stock (SEC Form 3)

      3 - Rafael Holdings, Inc. (0001713863) (Issuer)

      4/2/25 10:56:32 AM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David covered exercise/tax liability with 2,378 units of Class B Common Stock, decreasing direct ownership by 1% to 193,540 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      3/25/25 4:40:08 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      9/30/24 5:40:03 PM ET
      $RFL
      Real Estate
      Finance
    • Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

      SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

      6/18/24 6:12:11 PM ET
      $RFL
      Real Estate
      Finance
    • SEC Form SC 13G/A filed by Cyclo Therapeutics Inc. (Amendment)

      SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)

      2/14/24 2:44:54 PM ET
      $CYTH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care